Value of Platelet-Rich Plasma in Post Severe Acute Respiratory Syndrome Coronavirus 2

Aya abdelnasser hassani (Other)
Overall Status
Not yet recruiting ID

Study Details

Study Description

Brief Summary

The study will be conducted to evaluate :

The efficacy of Platelet Rich plasma in treatment of smell disorders post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via the growth factors involved in accelerating and enhancing healing.

Condition or Disease Intervention/Treatment Phase
  • Biological: platelets rich plasma
Early Phase 1

Detailed Description

Smell is essential sensory function for good quality of life as its preservation helps in identifying several harmful odors .

Viral URTIs can lead to olfactory disorders of varying degree and duration 70% of URTI caused by rhinovirus, adenovirus ,influenza and parainfluanza virus Smell disorders are divided into two types Quantitative (anosmia and hyposmia) Qualitative (parosmia and phantosmia) Anosmia is a total loss of smell . hyposmia is a decrease in the sense of smell. parosmia is a distortion of the smell in presence of an existing stimulus . Phantosmia (Cacosmia) is distortion of the smell in absence of an existing stimulus severe acute respiratory syndrome coronavirus2 (SARS-coV-2)which is a global pandemic started in china 2019 one of respiratory tract infection that affect olfaction and cause varying types of smell impairment.

Smell disorders seem to be more common in SARS-coV2 than other respiratory infections as in some patient persist for long time after resolution of respiratory symptoms Current evidence suggest that olfactory impairment results from propensity of SARS-coV2 for neuroinvasion and neurotrophic activities .

Majority of patients experience some level of smell impairment most often temporary as olfactory neuroepithelium has regenerative power .

European study published on 16 July 2020 reported that some patient affected by SARS -coV2 come solely with olfactory symptoms and most of patient recovered within 2 weeks ,smell not recovered in one quarter of patient 15 Once olfactory dysfunction persists more than 2 weeks a therapy should be considered to avoid persistent impairment of smell One of therapies can be used in ttt of smell disorders ( Platelet _rich plasma) PRP is a process in which a small amount of blood from test subject is separated by special centrifugation process.

PRP contains many growth factor which have a neuroregenerative feature as well as therapeutic effect

Study Design

Study Type:
Anticipated Enrollment :
88 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
Value of Platelet-Rich Plasma in Post Severe Acute Respiratory Syndrome Coronavirus 2 Smell Disorders
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: value of platlet rich plasma

Biological: platelets rich plasma
local ingection of platelets rich plasma

Outcome Measures

Primary Outcome Measures

  1. Change From Baseline in Loss of Smell on the Olfactory Determination etermination Rating scale for COVID-19 (ODoR-19) at 6 Weeks [baseline]

    40 of Participants With Treatment will be improved

Eligibility Criteria


Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  1. patient age above 18 who suffer from anosmia post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 more than two weeks

  2. Normal airway passage

  3. CT Nose and Para nasal sinuses does not show any nasal lesion

Exclusion Criteria:
  1. Lesions obstruct airway as nasal polyps, tumors, chronic sinusitis and severe nasal septum deviation

  2. Previous Sino nasal surgery

  3. Atrophic rhinitis

  4. Diabetic patients and those with medical history of bleeding disorders

  5. Recieving any medication affect platelets or bone marrow function for 2 weeks prior to testing

Contacts and Locations


No locations specified.

Sponsors and Collaborators

  • Aya abdelnasser hassani


None specified.

Study Documents (Full-Text)

None provided.

More Information


Responsible Party:
Aya abdelnasser hassani, Principal Investigator, Assiut University Identifier:
Other Study ID Numbers:
  • PRP in anosmia
First Posted:
May 27, 2022
Last Update Posted:
May 27, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 27, 2022